Company intelligence / Profile preview

Temple OrthoBiologics

New York, New York, United Statestempleorthobio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

TX-33 has shown promising results in preventing fibrosis in abdominal and pelvic surgeries and is being developed for orthopedic applications, particularly for knee injuries and surgeries. It's currently on track for human trials in knees as part of the FDA approval process in late 2025 or early 2026[3].

Therapeutic areas: OtherRheumatology
Modalities: Pharmaceutical-grade compoundadvanced biomaterialstargeted drug delivery
Industry: Biotech

Drug pipeline

1 asset

TX-33

Preclinical

Partnerships

Partnerships across USA, Netherlands, UK, and Canada

Beyond the preview

Go deeper on Temple OrthoBiologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Temple OrthoBiologics.

Explore the full profile